Tools
Tools
Fidan, D., Unal, B., Critchley, J. and Capewell, S. (2007) 'Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010'. Qjm-an International Journal of Medicine, Vol 100, Issue 5, pp. 277-289.
Full text not available from this repository.Abstract
Background: Coronary heart disease (CHD) in the UK affects similar to 3 million people, with > 100 000 deaths annually. Mortality rates have halved since the 1980s, but annual NHS treatment costs for CHD exceed 2 pound billion.
Aim: To examine the cost-effectiveness of specific CHD treatments in England and Wales.
Methods: The IMPACT CHD model was used to calculate the number of life-years gained (LYG) from specific cardiological interventions from 2000 to 2010. Cost-effectiveness ratios (costs per LYG) were generated for each specific intervention, stratified by age and sex. The robustness of the results was tested using sensitivity analyses.
Results: In 2000, medical and surgical treatments together prevented or postponed approximately 25 888 deaths in CHD patients aged 25-84 years, thus generating similar to 194 929 extra life-years between 2000 and 2010 (range 143 131-260 167). Aspirin and beta-blockers for secondary prevention following myocardial infarction or revascularisation, for angina and heart failure were highly cost-effective (<1000 pound per LYG). Other secondary prevention therapies, including cardiac rehabilitation, ACE inhibitors and statins, were reasonably cost-effective (1957 pound, 3398 pound and 4246 pound per LYG, respectively), as were CABG surgery (3239- pound 4601 pound per LYG) and angioplasty (3845- pound 5889 pound per LYG). Primary angioplasty for myocardial infarction was intermediate (6054- pound 12 pound 057 per LYG, according to age), and statins in primary prevention were much less cost-effective (27 pound 828 per LYG, reaching 69 pound 373 per LYG in men aged 35-44). Results were relatively consistent across a wide range of sensitivity analyses.
Discussion: The cost-effectiveness ratios for standard CHD treatments varied by over 100-fold. Large amounts of NHS funding are being spent on relatively less cost-effective interventions, such as statins for primary prevention, angioplasty and CABG surgery. This merits debate.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | acute myocardial-infarction risk-factor changes cost-effectiveness randomized-trials clinical-trials artery-disease primary prevention statin treatment bypass-surgery metaanalysis |
| Subjects: | WA Public Health > Preventive Medicine > WA 108 Preventive health services. Preventive medicine. Travel Medicine. WG Cardiovascular System > Heart. Heart Diseases > WG 200 General works |
| Faculty: Department: | Groups (2002 - 2012) > International Health Group |
| Digital Object Identifer (DOI): | https://doi.org/10.1093/qjmed/hcm020 |
| Depositing User: | Faye Moody |
| Date Deposited: | 22 Sep 2010 11:02 |
| Last Modified: | 06 Feb 2018 13:01 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/1192 |
Statistics
Actions (login required)
 |
Edit Item |